Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

I am a 75-year-old woman who isn’t prediabetic or diabetic. My BMI is 31.2. My doctor has prescribed a trial of metformin for ...

In light of recent revelations surrounding a new intranasal COVID-19 vaccine candidate, there is growing concern that the American public is once again being led into potentially dangerous territory ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...

The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one ...